'From' July 2012, new European wide legislation comes into effect whereby PharmaBio organizations that hold marketing authorizations for products in Europe will need to electronically report both serious and non-serious adverse reactions to one central point—EudraVigilance, the safety database of the European Medicines Agency (EMA), based in London. This is a major change, and requires organizations that carry out Pharmacovigilance to...
Read More
